Table 3.
Short-term oncologic outcomes of patients from randomized control trials
| Ref. |
LN |
Positive margin (CRM/distal) (%) |
||
| Open | Lap | Open | Lap | |
| Kang et al[40] | 18 (13-24) | 17 (12-22) | 7 (4.1)/NA | 5 (2.9)/NA |
| Ng eet al[45] | 12 (7) | 11.5 (7.9) | 1 (1.3)/NA | 2 (2.6)/NA |
| Lujan et al[31] | 11.57 (5.10) | 13.63 (6.26)a | 3 (2.9)/0 | 4 (4.0)/0 |
| Ng et al[39] | 13.0 (7) | 12.4 (6.7) | 2 (4.2)/NA | 3 (5.9)/NA |
| Guillou et al[7]/Jayne et al[12] | NA | NA | (14)/NA | (16)/NA |
| Braga et al[38] | 13.6 (6.9) | 12.7 (7.3) | 2 (2.4)/0 | 1 (1.2)/0 |
| Zhou et al[35] | NA | NA | NA | NA |
| Araujo et al[34] | 11.9 | 5.5a | NA | NA |
LN: Lymph nodes; CRM: Circumferential resection margin; NA: Not available.
a
P < 0.05 vs Open.